Literature DB >> 24718884

Specific MUC1 splice variants are correlated with tumor progression in esophageal cancer.

Kolsoum Rezaie Kahkhaie1, Omeed Moaven, Mohammad Reza Abbaszadegan, Mehdi Montazer, Mehran Gholamin.   

Abstract

BACKGROUND: Mucin 1 (MUC1) is a complex glycoprotein expressed on the apical surface of normal glandular epithelial cells. It plays a role in a number of biologic processes, and its overexpression is associated with various malignancies. A growing body of literature suggests that MUC1 is a potential diagnostic and therapeutic marker. Increasing numbers of variants are being identified for the MUC1 gene, but their role in carcinogenesis is unclear. Alternative splicing and a specific region on a variable number of tandem repeats are characteristic features of MUC1. However, the underlying mechanisms, overall prevalence, and the function of various MUC1 isoforms are not well characterized.
METHODS: In the present study, mRNA expression of nine variants of the MUC1 gene (A-D, X-Z, REP, SEC) was evaluated in normal and tumor tissues obtained from 50 patients with esophageal squamous cell carcinoma (ESCC). Associations between expression of various isoforms of MUC1 and important clinicopathologic factors were studied.
RESULTS: Specific MUC1 splice variants (i.e., MUC1/C, D, and Z) are correlated with tumor progression in ESCC, whereas MUC1/B-previously suggested as a "normal" variant in some other cancers-has protective effects and is associated with more favorable tumor behavior and better prognosis.
CONCLUSIONS: Specific isoforms of ESCC are associated with prognosis. Further characterization of different isoforms of MUC1 and their biologic effects is needed to explore their diagnostic and prognostic potential in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24718884     DOI: 10.1007/s00268-014-2523-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus.

Authors:  P Guillem; V Billeret; M P Buisine; J F Flejou; M Lecomte-Houcke; P Degand; J P Aubert; J P Triboulet; N Porchet
Journal:  Int J Cancer       Date:  2000-12-15       Impact factor: 7.396

2.  Mucin 1 and vascular endothelial growth factor C expression correlates with lymph node metastatic recurrence in patients with N0 esophageal cancer after Ivor-Lewis esophagectomy.

Authors:  Zhi-Gang Sun; Zhou Wang; Xiang-Yan Liu; Fan-Ying Liu
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

3.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

Review 4.  Pathways of O-glycan biosynthesis in cancer cells.

Authors:  I Brockhausen
Journal:  Biochim Biophys Acta       Date:  1999-12-06

5.  Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients.

Authors:  Eirikur Saeland; Ana I Belo; Sandra Mongera; Irma van Die; Gerrit A Meijer; Yvette van Kooyk
Journal:  Int J Cancer       Date:  2011-11-28       Impact factor: 7.396

6.  Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.

Authors:  Deepak Raina; Michio Kosugi; Rehan Ahmad; Govind Panchamoorthy; Hasan Rajabi; Maroof Alam; Takeshi Shimamura; Geoffrey I Shapiro; Jeffrey Supko; Surender Kharbanda; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2011-03-18       Impact factor: 6.261

7.  Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling.

Authors:  Jian Ren; Yongqing Li; Donald Kufe
Journal:  J Biol Chem       Date:  2002-03-04       Impact factor: 5.157

8.  Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.

Authors:  Neeley Remmers; Judy M Anderson; Erin M Linde; Dominick J DiMaio; Audrey J Lazenby; Hans H Wandall; Ulla Mandel; Henrik Clausen; Fang Yu; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

9.  The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop.

Authors:  Selvi Ramasamy; Sekhar Duraisamy; Sergei Barbashov; Takeshi Kawano; Surender Kharbanda; Donald Kufe
Journal:  Mol Cell       Date:  2007-09-21       Impact factor: 17.970

10.  Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms.

Authors:  Lixin Zhang; Anda Vlad; Christine Milcarek; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2012-09-02       Impact factor: 6.968

View more
  10 in total

1.  Biological and Clinicopathological Significance of Cripto-1 Expression in the Progression of Human ESCC.

Authors:  Reihaneh Alsadat Mahmoudian; Mohammad Reza Abbaszadegan; Mohammad Mahdi Forghanifard; Meysam Moghbeli; Faezeh Moghbeli; Jamshidkhan Chamani; Mehran Gholamin
Journal:  Rep Biochem Mol Biol       Date:  2017-04

2.  Prognostic alternative splicing signatures and underlying regulatory network in esophageal carcinoma.

Authors:  Zu-Cheng Xie; Hua-Yu Wu; Fu-Chao Ma; Yi-Wu Dang; Zhi-Gang Peng; Hua-Fu Zhou; Gang Chen
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 3.  Genetic variants of mucins: unexplored conundrum.

Authors:  Sushil Kumar; Eric Cruz; Suhasini Joshi; Asish Patel; Rahat Jahan; Surinder K Batra; Maneesh Jain
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

Review 4.  Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer.

Authors:  Jos P M van Putten; Karin Strijbis
Journal:  J Innate Immun       Date:  2017-01-05       Impact factor: 7.349

5.  Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma.

Authors:  Jian-Rong Sun; Chen-Fan Kong; Yan-Ni Lou; Ran Yu; Xiang-Ke Qu; Li-Qun Jia
Journal:  Front Genet       Date:  2020-07-22       Impact factor: 4.599

6.  Applying Subtractive Hybridization Technique to Enrich and Amplify Tumor-Specific Transcripts of Esophageal Squamous Cell Carcinoma.

Authors:  Reihaneh Alsadat Mahmoudian; Mohammad Reza Abbaszadegan; Mehran Gholamin
Journal:  Pathol Oncol Res       Date:  2016-07-15       Impact factor: 3.201

7.  Crosstalk between MMP-13, CD44, and TWIST1 and its role in regulation of EMT in patients with esophageal squamous cell carcinoma.

Authors:  Reihaneh Alsadat Mahmoudian; Maryam Lotfi Gharaie; Mohammad Reza Abbaszadegan; Ali Alasti; Mohammad Mahdi Forghanifard; Atena Mansouri; Mehran Gholamin
Journal:  Mol Cell Biochem       Date:  2021-02-19       Impact factor: 3.396

8.  Clinical and prognostic significance of MUC1 expression in patients with esophageal squamous cell carcinoma after radical resection.

Authors:  Zhi-Gang Sun; Li Yu; Wei Gao; Zhou Wang; Liang-Ming Zhu
Journal:  Saudi J Gastroenterol       Date:  2018 May-Jun       Impact factor: 2.485

Review 9.  Genetic and molecular bases of esophageal Cancer among Iranians: an update.

Authors:  Mohammad Reza Abbaszadegan; Vahideh Keyvani; Meysam Moghbeli
Journal:  Diagn Pathol       Date:  2019-08-31       Impact factor: 2.644

10.  Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression.

Authors:  Beibei Ni; Jun Hu; Dianke Chen; Li Li; Daici Chen; Jianping Wang; Lei Wang
Journal:  Oncol Lett       Date:  2016-07-13       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.